Carboxy-terminal cross-linked telopeptide of type II collagen (CTX-II)

Carboxy-terminal cross-linked telopeptide of type II collagen (CTX-II) is a peptide fragment generated during the degradation of type II collagen, the major protein constituent of articular cartilage. CTX-II is released into the body fluids following collagen type II breakdown and can be measured in urine. Elevated urinary CTX-II levels are associated with increased cartilage degradation and are used as a biomarker in the diagnosis and monitoring of osteoarthritis and other joint diseases. Unlike classical "targets" such as enzymes or receptors, CTX-II does not mediate biological activity but serves as an indicator of tissue breakdown, particularly in cartilage pathologies[2]. Key technical notes: - **CTX-II is a *biomarker*, not a drug target**: it is not an enzyme, receptor, or other typical therapeutic target, but a degradation product used to monitor disease progression[2][1]. - **CTX** (without "-II") may refer to type I collagen degradation and is a *different* clinical marker[1][3]. Your reference to type II collagen specifically is correct for cartilage breakdown and osteoarthritis[2]. - No therapies target CTX-II itself; instead, the measurement is used to assess degradation resulting from disease processes or response to interventions in conditions like osteoarthritis[2].

Other names

C-terminal cross-linked telopeptide of type II collagenCTX-IIC-telopeptide of type II collagen

Not applicable (biomarker, not directly targeted)